Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1053323.RA6NHA_08fpGoxE7dXhRkeNKqJ0r73GAfNBW_ASjWLTg8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1053323.RA6NHA_08fpGoxE7dXhRkeNKqJ0r73GAfNBW_ASjWLTg8130_assertion type Assertion NP1053323.RA6NHA_08fpGoxE7dXhRkeNKqJ0r73GAfNBW_ASjWLTg8130_head.
- NP1053323.RA6NHA_08fpGoxE7dXhRkeNKqJ0r73GAfNBW_ASjWLTg8130_assertion description "[The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1053323.RA6NHA_08fpGoxE7dXhRkeNKqJ0r73GAfNBW_ASjWLTg8130_provenance.
- NP1053323.RA6NHA_08fpGoxE7dXhRkeNKqJ0r73GAfNBW_ASjWLTg8130_assertion evidence source_evidence_literature NP1053323.RA6NHA_08fpGoxE7dXhRkeNKqJ0r73GAfNBW_ASjWLTg8130_provenance.
- NP1053323.RA6NHA_08fpGoxE7dXhRkeNKqJ0r73GAfNBW_ASjWLTg8130_assertion SIO_000772 23413279 NP1053323.RA6NHA_08fpGoxE7dXhRkeNKqJ0r73GAfNBW_ASjWLTg8130_provenance.
- NP1053323.RA6NHA_08fpGoxE7dXhRkeNKqJ0r73GAfNBW_ASjWLTg8130_assertion wasDerivedFrom befree-2016 NP1053323.RA6NHA_08fpGoxE7dXhRkeNKqJ0r73GAfNBW_ASjWLTg8130_provenance.
- NP1053323.RA6NHA_08fpGoxE7dXhRkeNKqJ0r73GAfNBW_ASjWLTg8130_assertion wasGeneratedBy ECO_0000203 NP1053323.RA6NHA_08fpGoxE7dXhRkeNKqJ0r73GAfNBW_ASjWLTg8130_provenance.